4726.TWO Mycenax Biotech
- Market cap
- TWD 4.29B
- P/E
- -
- P/B
- 3.12x
- ROE
- -28.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 4726.TWO undervalued?
Graham numberThe Graham number of Mycenax Biotech cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Mycenax Biotech fundamental analysis
No fundamental analysis for Mycenax Biotech yet.
Mycenax Biotech stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Mycenax Biotech
Mycenax Biotech Inc. provides biopharmaceutical services and solutions for drug development and production in Taiwan. The company's services include program evaluation/confirmation, cell line development and construction, process development technology platforms, drug characterization analysis, establishment of testing methods, and PIC/S GMP drug production. It offers CDMO services, including integrated biologics development services, specialized modalities, manufacturing, a…
Full company profileMycenax Biotech financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Mycenax Biotech annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 319M | 211M | 391M | 665M | 774M | 732M | 653M | 684M | 740M | 800M |
| Gross Profit | 140M | 14.1M | 133M | 187M | 138M | -114M | -375M | -241M | -181M | -155M |
| Operating Income | -121M | -321M | -229M | 46.3M | -92.5M | -414M | -603M | -461M | -405M | -356M |
| EBITDA | -58.0M | -206M | -105M | 166M | 82.8M | -161M | -342M | -136M | -136M | -35.2M |
| Net Income | -188M | -274M | -218M | 30.9M | -89.9M | -454M | -683M | -467M | -449M | -399M |
| EPS | -1.71 | -2.50 | -1.98 | 0.24 | -0.59 | -2.21 | -3.32 | -2.26 | -2.16 | -1.93 |
| Balance Sheet | ||||||||||
| Total Assets | 1.31B | 1.12B | 1.41B | 1.75B | 3.14B | 4.45B | 3.77B | 3.37B | 3.26B | 3.28B |
| Total Liabilities | 169M | 212M | 306M | 541M | 1.23B | 1.35B | 1.32B | 1.34B | 1.66B | 1.87B |
| Shareholders' Equity | 1.14B | 907M | 1.10B | 1.21B | 1.91B | 3.11B | 2.45B | 2.02B | 1.60B | 1.41B |
| Cash & Short-term Investments | 342M | 216M | 194M | 291M | 287M | 1.32B | 519M | 270M | 225M | 264M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -45.6M | -180M | -141M | 174M | -146M | -150M | -131M | -192M | -27.2M | 171M |
| Capital Expenditure | 91.5M | 118M | 178M | 260M | 1.10B | 627M | 298M | 331M | 99.1M | 198M |
| Free Cash Flow | -137M | -301M | -320M | -88.1M | -1.26B | -789M | -429M | -522M | -126M | -26.2M |
| Ratios | ||||||||||
| ROE | -16.5% | -30.3% | -19.8% | 2.6% | -4.7% | -14.6% | -27.9% | -23.1% | -28.1% | -28.3% |
| ROA | -14.3% | -24.5% | -15.5% | 1.8% | -2.9% | -10.2% | -18.1% | -13.9% | -13.8% | -12.2% |
| Net Profit Margin | -59.1% | -129.8% | -55.8% | 4.7% | -11.6% | -61.9% | -104.6% | -68.3% | -60.6% | -49.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Mycenax Biotech dividends
Mycenax Biotech has not paid dividends in the last 9 fiscal years.
Who owns Mycenax Biotech
- Insiders 47.55%
- Institutions 0.04%
- Public & others 52.41%
- Shares outstanding 207M
- Free float 113M
Mycenax Biotech company profile
- Company name
- Mycenax Biotech
- Ticker
- 4726.TWO
- ISIN
- TW0004726005
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- No. 66, Shengyi 2nd Rd., Zhubei, Taiwan, 302041
- Phone
- 886 3 667 0880
- Website
- mycenax.com
About Mycenax Biotech
Mycenax Biotech Inc. provides biopharmaceutical services and solutions for drug development and production in Taiwan. The company's services include program evaluation/confirmation, cell line development and construction, process development technology platforms, drug characterization analysis, establishment of testing methods, and PIC/S GMP drug production. It offers CDMO services, including integrated biologics development services, specialized modalities, manufacturing, and quality services. It also offers bispecific antibody production, and NaxLeap, a transposon system; PlasMX, a plasmid DNA manufacturing; differential scanning fluorimetry; antibody-drug conjugates; cell and gene therapy, including allogeneic immune cell solutions, and ExoMX, a exosome manufacturing; and white papers, articles, and posters and flyers. The company was founded in 2001 and is headquartered in Zhubei, Taiwan.
Mycenax Biotech management
3- Ms. Pei-Jiun Chen Ph.D.President CEO & Chairman
- Ms. Liru YehAssistant Vice President of Finance & Accounting Division
- Mr. Chin-Hao LiangAssociate VP of Administration & Management Division